PRNewsWire
01 Jan 2026, 15:00 UTC · 36w ago
Verdict
Headline takes no side. We score XOMA −0.90 across three claims — strongly bearish.
−0.90strongly bearish
More negative than 91% of ticker scores this week
What the story claims
3 claims · scored −1 bearish … +1 bullish
Rezolute's Phase 3 sunRIZE study for ersodetug failed to meet its primary endpoint and key secondary endpoint regarding hypoglycemia events.
So whatThe failure of a Phase 3 clinical trial for a key development asset typically leads to significant loss of projected future revenue and asset valuation.
More negative than 98% of claims this week
Pomerantz LLP is investigating XOMA Royalty Corporation for potential securities fraud or unlawful business practices following the trial results.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 2 movers · tap to explore
More negative than 80% of claims this week
XOMA's stock price dropped 22.76% ($7.82 per share) to close at $25.39 on December 19, 2025, following the trial news.
So whatThis confirms the market has already partially priced in the negative clinical outcome, though it establishes a new, lower valuation baseline.
More negative than 67% of claims this week
Which stocks this story touches
More negative than 91% of ticker scores this week
The company is facing a securities fraud investigation and its stock plummeted after a partner's Phase 3 study failed to meet primary endpoints.
More negative than 84% of ticker scores this week
The company's Phase 3 sunRIZE study for ersodetug failed to meet its primary and key secondary endpoints.
More negative than 82% of ticker scores this week
The company is the subject of a newly filed class action lawsuit.
More negative than 74% of ticker scores this week
The company is mentioned in the context of a proposed class action settlement.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
PRNewsWire
3h ago
+51.1%
Price is moving against the score
$40.17 vs $26.59 close before publication (Dec 31) · not market-adjusted
XOMA chart →
